Effect of BET inhibitor, mivebresib, dactolisib or LCL-161 on protein expressions in AML cells with MECOM rearrangement and high expression of EVI1

ABSTRACT: Patient-derived AML194 (acute myeloid leukemia with inv3(q21;q26.2)) cells were treated in duplicate with 0 nM or 500 nM of mivebresib, 500 nM of dual PI3K/mTOR inhibitor dactolisib or 1000 nM of IAP antagonist LCL-161 for 24 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment with these small molecules in MECOM-rearranged AML cells with EVI1 overexpression.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Antrix Jain  

LAB HEAD: Dr Kapil Bhalla

PROVIDER: PXD063413 | Pride | 2026-02-16

REPOSITORIES: Pride